News + Filings Transactions
|
Readnour Robin Shane
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/07/2023 | AN2 Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 23.7k | $5.91 | $140.3k | | 06/07/2023 |
| 05/12/2022 | AN2 Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 20.7k | $17.28 | $358.1k | | 05/12/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Common Stock | 285.2k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Common Stock | 333.1k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Common Stock | 61.5k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Common Stock | 71.8k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Purchase | Common Stock | 70.7k | $15.00 | $1.1M | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Purchase | Common Stock | 82.6k | $15.00 | $1.2M | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Series A Convertible Preferred Stock | 285.2k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Series A Convertible Preferred Stock | 333.1k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 61.5k | $0.00 | $0 | See footnotes | 03/29/2022 |
| 03/29/2022 | AN2 Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 71.8k | $0.00 | $0 | See footnotes | 03/29/2022 |
|